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The  treatment  of chronic  hepatitis  C  virus  infection  is  rapidly  evolving  with  the entry  into  the  therapeutic
armamentarium  of  a series  of  new  and  highly  effective  direct  antiviral  agents,  targeted  to the  different
virus  structures  involved  in hepatitis  C  virus  replication  and  assembly.  Sofosbuvir  is  considered,  without
controversies,  the most  promising  single  direct  antiviral  agent  in  the  current  scenario.  The  pharmacolog-
ical  properties  of sofosbuvir  allow  a single  oral  daily  administration  and  ensure  a favourable  drug–drug
interaction  proﬁle,  compared  to  other  direct  antiviral  agents.  Clinical  development  of  sofosbuvir  has
been  conducted  with  the  strategy  of  positioning  it as  the  backbone  drug  of  several  combination  regimes,
including  triple  therapy  with  pegylated  interferon  and  ribavirin,  but  also  IFN-free  regimen  with  ribavirin
alone  as well  as  with  complementary  direct  antiviral  agents  directed  against  other  virus  targets.  Based
on  available  data  and  International  guidelines  sofosbuvir  is indicated  in  combination  with  pegylated
interferon  and ribavirin  in  patients  infected  with  hepatitis  C virus  1 to 6 that  can  take  interferon,  and
this  regimen  is  particularly  efﬁcacious  in  those  who  have  not  received  any  previous  antiviral  treatment.
The  pangenotypic  activity,  excellent  safety  (even  in  advanced  liver  disease)  make  sofosbuvir  the  ideal
backbone  for  combination  therapy  in all  hepatitis  C virus  patients  subgroups,  the limiting  factors  being
safety  and tolerability  of the  combined  direct  antiviral  agent  rather  than  those  of sofosbuvir  itself.
© 2014  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  
ND lic. Background
Hepatitis C represents a leading healthcare challenge in many
arts of the world, being one of the leading causes of cirrhosis, of
nd-stage liver disease and of hepatocellular carcinoma. Chronic
CV infection associates with a signiﬁcant medical and economic
urden that is estimated will rise further in the coming years in the
bsence of an effective strategy of control and treatment interven-
ions [1,2].
Treatment of chronic HCV infection with PEG-IFN and ribavirin,
nd more recently with PEG-IFN plus ribavirin and ﬁrst genera-
ion protease inhibitors (Telaprevir and Boceprevir) for HCV-1, have
een the standard of care until recently. Although there is solid
vidence that patients achieving a sustained virological response
Open access under CC BY-NC-SVR) with deﬁnitive virus eradication with these regimes have a
lear clinical beneﬁt on long term disease complications and sur-
ival, this favourable outcome is achieved only in a subgroup of
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niversità di Padova, Via Giustiniani 2, 35100 Padova, Italy. Tel.: +39 0498212293;
ax: +39 0498211826.
E-mail address: alfredo.alberti@unipd.it (A. Alberti).
ttp://dx.doi.org/10.1016/j.dld.2014.09.028
590-8658/© 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Oppatients and in a small minority of those with more advanced liver
disease, which are in more evident and urgent need of cure [3,4].
Furthermore, side effects are frequent and may  be severe in individ-
ual cases, and many patients cannot be initiated on therapy due to
contraindications, or are reluctant to receive Interferon. Therefore,
the clinical effectiveness of these treatment has been extremely
limited as to the control of the burden of the infection and disease in
the infected population and there is an urgent need for better toler-
ated and more effective treatments, particularly for those patients
for whom PEG-IFN is not an option, those with more advanced liver
disease, and those who  have already taken and failed available ther-
apies. The recent development of a series of new direct antiviral
agents (DAAs) directed against HCV target proteins used by the
virus for replication and assembly, has opened a new era in the
treatment of hepatitis C, with the concrete prospective of moving
rapidly from IFN-based regimes towards all oral IFN-free combi-
nations characterized by higher efﬁcacy and improved tolerability
and safety [5]. Sofosbuvir, a nucleotide HCV polymerase inhibitor
with pangenotypic activity, represents the bridge between these
ense.two strategies and appears as the essential backbone of most future
DAAs combinations due to its high antiviral potency, pangenotypic
activity, high barrier to resistance, favourable pharmacokinetics
and excellent tolerability and safety proﬁle.
en access under CC BY-NC-ND license.
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Fig. 1. Sofosbuvir metabolism. The drug is phosphorylated to its active form in the
hepatocytes, and this activation occurs via human cathepsin A, Carboxylesterase 1
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was extensively studied and characterized by analyzing mutations
in the HCV NS5B gene using both standard population sequenc-nd histidine triad nucleotide binding protein 1.
. Sofosbuvir
.1. Mechanism of action and pharmacokinetic properties
The  HCV-RNA genome encodes a large polyprotein that is
leaved by host and virus proteases into 10 different products. The
on-structural proteins are all involved in virus replication and
ssembly and are located towards the c-terminus part, behind the
tructural core and envelope proteins. All the NS proteins are poten-
ial targets for antiviral drugs. The NS3-4A protease is targeted by
rotease inhibitors (PI) which include the ﬁrst DAAs used in clin-
cal practice against HCV (Boceprevir and Telaprevir), the recently
pproved Simeprevir and a series of new generation PI under devel-
pment and clinical testing. NS5A is the target of NS5A inhibitors,
uch as Daclatasvir, Ledipasvir and other compounds.
Sofosbuvir is the ﬁrst in class NS5B polymerase inhibitor [6,7]:
t is an HCV speciﬁc uridine nucleotide prodrug that blocks replica-
ion of HCV in an highly efﬁcient manner by inhibiting the active,
atalytic site of the HCV NS5B polymerase and terminating the
eneration of the HCV-RNA chains (Chain terminator). The HCV
olymerase is an RNA-dependent RNA polymerase with a crucial
ole in the synthesis of new RNA genomes of HCV. SOF is phos-
horylated to its active form in the hepatocytes, and this activation
ccurs via human cathepsin A, Carboxylesterase 1 and histidine
riad nucleotide binding protein 1 (Fig. 1). The active compound
hen competes with natural nucleotides causing termination of
CV-RNA replication. The active triphosphate form of SOF targets
he highly conserved active site of the HCV polymerase, and for this
eason SOF has pangenotypic antiviral activity, although with some
ifferences in potency, which has been conﬁrmed in vitro experi-
ents using the HCV replicon system. Dephosphorylation of active
OF produces inactive metabolites such as GS-331007, which are
leared mainly by the kidney.
Oral SOF is absorbed rapidly, with a median time to peak con-
entration (Tmax) of 1 h (0.5–3 h). Pharmacokinetics data indicate
hat SOF can be administered without considering food intake.
Demographic variables, such as age, sex, BMI, race, advanced
iver disease with cirrhosis, as well as concomitant medications
ave been shown not to affect, or to have only a marginal effect,
n pharmacokinetics of SOF and of its metabolite in HCV infected
ndividuals. Pharmacokinetic data indicate that SOF can be admin-
stered without dose adjustments in the presence of mild or
oderate renal impairment (eFR > 30 mL/min/1.73 m2). On the
ther hand, the use of SOF with severe renal impairment or end-
tage renal disease requiring haemodialysis is not recommended.er Disease 46 (2014) S174–S178 S175
Studies conducted in patients with moderate hepatic impair-
ment (Child–Pugh B cirrhosis) would indicate that SOF is well
tolerated in these patients with no need for dose modiﬁcations.
A  major advantage of SOF compared to most other DAAs against
HCV derives from the evidence that SOF and its major metabo-
lite are not metabolized by the cytochrome (CYT) P450 enzymes
or by uridine diphosphate glucuroryltransferase (UGT) and there-
fore do not cause any induction or inhibition of these enzymes.
On the other hand, SOF is a substrate of P-glycoprotein (PgP) and
of breast cancer resistance protein (BCRP) and therefore drugs or
substances which are inducers of these pathways should be sus-
pected to affect SOF metabolism and to reduce its therapeutic
efﬁcacy. This means, in practical terms, that certain anticonvulsants
such as cabarmazepine, phenytoin, phenobarbital, oxcarbazine,
and antimycobacterials such as rifantin, rifampin and rifapentine
can decrease the concentration and therapeutic effect of SOF and
should not be coadministered.
As  regards the antiretroviral agents used to treat HIV coinfected
patients, available data indicate that no dose adjustment of SOF
and of most reverse transcriptase inhibitors is needed when these
drugs are combined [8]. However, coadministration of SOF with
tipranavir/ritonavir is not recommended.
Most importantly for the clinical setting, coadministration of
SOF has no clinically signiﬁcant effect on the pharmacokinetics of
the immunosuppressive drugs commonly used in liver transplant
patients, such as cyclosporine A and tacrolimus, and dose adjust-
ments are not needed [9]. Finally, SOF can be combined with daily
methadone, without clinically signiﬁcant drug–drug interactions
(DDI) [10]. The same is true for oral hormonal contraceptives that
can be used during SOF-based treatment without interference with
the antiviral activity while maintaining their contraceptive efﬁcacy.
2.2. Resistance proﬁle
The  rapid rate of HCV replication, combined with a lack of error
proofreading by the viral RNA polymerase, are associated with
a high frequency of mutations in the HCV-RNA genome. This is
reﬂected in the high degree of genomic diversity which typically
characterizes the virus quasispecies in individual cases. Mutations
which confer reduced sensitivity or resistance to HCV DAAs may
pre-exist before the drug is administered and/or may emerge or be
selected during therapy and may  become the predominant species,
if they possess adequate replication ﬁtness. This may result in treat-
ment failure, as seen in some patients treated with Boceprevir or
Telaprevir in association with PEG-IFN and ribavirin. SOF appears
to have an excellent high barrier to resistance, clearly superior to
that of all other non-nucleotide inhibitors, PIs and NS5A inhibitors
developed or under development for HCV. This is mainly because
SOF is directed against a highly conserved, active site of the virus
polymerase, which is essential for virus replication. In vitro expo-
sure to SOF has been shown to select the NS5B S282T mutation in
GT1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a replicons. This mutation reduces
the sensitivity of HCV to SOF, but also signiﬁcantly reduces HCV
replicative ﬁtness to 1–10% of that of the wild type virus. The S282T
mutants remain fully sensitive to ribavirin, which should always be
administered with SOF in the absence of other combined DAAs, and
this is expected to greatly limit the emergence of the poorly repli-
cating strains resistant to SOF [11]. Furthermore, S282T mutants
remain sensitive to other classes of DAAs without cross-resistance.
These data taken together indicate that SOF has a high barrier to
resistance, as conﬁrmed in clinical studies [12].
In the phase II and phase III SOF studies, virological resistanceing and deep sequencing, in order to detect even very low levels
of potentially resistant mutations. In addition, HCV-RNA from
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atients showing mutations in NS5B were cloned into an in vitro
eplicon system and tested for any associated reduction in suscepti-
ility to SOF. According to these studies, none of the patients treated
ith SOF in phase II or phase III trials experienced virological break-
hrough during therapy. The NS5B S282T mutation was detected in
nly 1 patient with relapse. The mutation reversed to wild type
4 weeks after cessation of SOF. In phase III studies, no drug resis-
ance or drug associated breakthrough was observed in any of the
atients. None of those who relapsed had the S282T mutation by
eep sequence analysis. Although other NS5B substitutions were
etected, they were not associated with a phenotypic change in
OF or RBV sensitivity in vitro.
These data further conﬁrm in a most solid manner the high bar-
ier to resistance of SOF and indicate that the drug can be used in
CV infected patients, even in a simpliﬁed dual combination with
BV, without generating resistance, and this is true for all major
CV genotypes, including HCV-1a.
.3. Place in therapy
Sofosbuvir has been evaluated in phase II and phase III clinical
rials in combination with PEG-IFN and ribavirin, as well as in all
ral regimens with ribavirin or combined with other DAAs. The
esults of these studies are described in detail in another chapter
f this supplement issue [13]. These studies clearly indicate that
ofosbuvir represents a major advance in the treatment of hepatitis
, and the ideal backbone for IFN based and for IFN free regimens for
CV patients infected with any HCV genotype and suffering from
ny stage of liver disease. The European (EMA) labelling indications
or SOF are summarized in Table 1.
.4. International guidelines (Table 2)
The American Association for the Study of Liver Diseases
AASLD) was the ﬁrst to develop guidelines for the use of SOF in
linical practice [14]. In these guidelines, different SOF containing
egimens are recommended for different patient subgroups with
ifferent ratings of strength and quality of supporting evidence
Table 2).
able 1
he  European (EMA) labelling indications for sofosbuvir treatment. Sofosbuvir is
lso listed in the European SmCP of simeprevir.
Patient subgroupsa Regimenb Duration
Patients with HCV-1, 4, 5, 6 SOF + RBV + PEG-IFN 12 weeksc
Patients with HCV-1, 4, 5, 6
who are intolerant or have
contraindications  to PEG-IFN
SOF + RBV 24 weeks
Patients with HCV-2 SOF + RBV 12 weeksc
Patients with HCV-3
SOF  + RBV + PEG-IFN 12 weeksc
SOF + RBV 24 weeks
Patients listed for liver
transplant
SOF + RBV Up to liver
transplantation
Patients infected with HCV1 or
HCV-4, independently of
previous treatment history
SMV + SOF (±RBV)d 12 weeks
bbreviations: SOF, sofosbuvir; PEG-IFN, pegylated interferon; RBV, ribavirin; SMV,
imeprevir.
a Including patients coinfected with HIV.
b SOF = 400 mg  daily; RBV = 1.000–1.200 mg  daily based on body weight <75 kg,
75  kg; PEG-IFN-2a = 180 g once weekly or PEG-IFN-2b = 1.5 mcg/kg one weekly.
c Extension to 24 weeks to be considered in patients who have one or more
actors  which have been historically associated with reduced response to IFN-
ased therapy (including advanced ﬁbrosis/Cirrhosis) high baseline HCV-RNA levels,
fro-American origin, IL28B non-CC, previous null response to PEG-IFN and RBV
reatment).
d SMV  + SOF to be used only in patients who are intolerant or ineligible for PEG-IFN
ontaining  therapies, and have an urgent need for treatment. RBV should be added
r not based on the treating physician decision at the single patient individual level.er Disease 46 (2014) S174–S178
2.4.1. SOF plus PEG-IFN plus RBV for 12 weeks (The Neutrino
Regimen)
This  regimen is recommended with high levels of strength and
quality (Class I, level A) for naïve and relapser HCV-1 infected
patients who  are eligible for IFN, independently of the HCV-1 sub-
type and stage of liver disease. This same regimen is also indicated,
with a lower strength and/or quality for several patient subgroups
including: Naïve and relapser patients with HCV-3, HCV-4 and HCV-
5 or 6, previous non-responder patients with HCV-1, 2, 3, 4, 5, 6.
Triple therapy with SOF plus PEG-IFN plus RBV for 12 weeks, fol-
lowed by additional 12 weeks of PEG-IFN plus RBV was indicated
even for patients who have failed triple therapy with Boceprevir or
Telaprevir, although there are no data to support this indication.
2.4.2.  SOF plus RBV
This  simpliﬁed all oral regimen, given for only 12 weeks, is rec-
ommended with high levels of strength and quality (Class I, Level A)
for either naïve or experienced HCV-2 patients. SOF plus RBV, but
for 24 weeks, is instead indicated for HCV-3 and for IFN-ineligible
naïve HCV-1 patients and also for naïve and experienced IFN ineligi-
ble HCV-4, 5, and 6 patients. This same regimen is also considered
a possible alternative option for HCV-1 patients who  have failed
triple therapy with BOC or TVR, but with no data to support it.
2.4.3.  SOF plus SMV with or without RBV
This regimen is recommended for IFN ineligible and for experi-
enced HCV-1 patients with Class I, level B.
The European Association for the study of the Liver (EASL) also
produced updated Guidelines for the treatment of HCV in April
2014 [15]. These guidelines consider the use of SOF in combina-
tion with PEG-IFN and RBV, as well as in all oral combinations with
RBV, with Simeprevir, and with Daclatasvir.
The EASL guidelines list a number of alternative options for the
treatment of the different patient categories, giving the level of
strength and quality of supporting evidence for each option.
As  regards SOF-based regimens, the European guidelines give
the following indications.
2.4.4.  SOF plus PEG-IFN plus RBV for 12 weeks
Indicated for HCV-1 infected patients, if eligible for PEG-IFN and
RBV, independently of HCV-1 subtype, previous therapy, and stage
of liver disease (A1). The same regimen is also indicated for HCV-3
(A2) HCV-4 (B1) and HCV-5, 6 (B1). This regimen can also be con-
sidered as a possible alternative for HCV-2 patients with cirrhosis.
2.4.5.  SOF plus RBV for 12 weeks
Indicated as the treatment of choice for HCV-2, with the possible
extension to 16–20 weeks in patients with cirrhosis, particularly in
those who have failed PEG-IFN plus ribavirin combination therapy.
2.4.6. SOF plus RBV for 24 week
May be used in HCV-1 infected patients who are intolerant or
have contraindications for PEG-IFN, but only in the absence of avail-
ability of other, more efﬁcacious, IFN-free regimens.
It is also suggested for HCV-3, but with the warning that it might
be suboptimal in patients with cirrhosis who have failed PEG-IFN
plus ribavirin combination therapy.
This same regimen is also indicated for HCV-4, 5, 6 infected
patients who  are intolerant or have contraindications for PEG-IFN
(low strength and quality).
2.4.7.  SOF plus SMV for 12 weeks
This regimen is indicated for HCV-1 and HCV-4 infected patients,
the addition of ribavirin should be considered in patients with cir-
rhosis or with previous failure to achieve SVR with PEG-IFN and
RBV.
A. Alberti, S. Piovesan / Digestive and Liver Disease 46 (2014) S174–S178 S177
Table  2
SOF-based regimens from International guidelines.
Regimen Place in therapy Quality of
evidence/strength of
recommendationsa
SOF + RBV × 12 weeks EASL  HCV-2 (Naives and Experienced) I/AAASLD HCV-2 (Naives and Experienced) A/1
SOF  + RBV × 24 weeks
AASLD
HCV-3
Non  responders I/B
Naives and relapsers IIa/A
HCV-1 Naives (IFN ineligible) IIb/B
HCV-4
Naives (IFN ineligible) IIb/B
Experienced IIa/C
HCV-5/6 Experienced No data
EASL
HCV-3 Naives/Experienced (excluding
cirrhotics)
A/2
HCV-1  Naives/Experienced (only if IFN-non
eligible, urgent and in the absence of
better alternatives)
B/2
HCV-4 Naives/Experienced (only if IFN-non
eligible)
C/2
HCV-5/6 Naives/Experienced (only if IFN-non
eligible)
C/2
SOF  + Peg-IFN + RBV × 12 weeks
AASLD
HCV-1 Naives I/A
HCV-2 Experienced IIa/B
HCV-3
Naives IIa/A
Experienced IIa/B
HCV-4/5/6
Naives IIa/B
Experienced IIa/C
EASL
HCV-1 Naives/Experienced A/1
HCV-2 Cirrhotics/Experienced B/1
HCV-3 Naives/Experienced A/2
HCV-4 Naives/Experienced B/1
HCV-5/6 Naives/Experienced B/1
SOF  + RBV (with or without PEG-IFN) × 24 weeks AASLD HCV-1 Who  have failed Triple (BOC/TVR)
Therapy
No data
SOF  + SMV  × 12 weeks (with or without RBV)
AASLD HCV-1
Naives (IFN-non eligible) I/B
Experienced IIa/B
EASL
HCV-1 Naives/Experienced B/1
HCV-4 Naives/Experienced B/2
SOF  + DCV × 12–24 weeks (with or without
RBV) EASL
HCV-1
Naives (12 weeks) B/1
Experienced (24 weeks) (Including
BOC/TVR failures)
B/1
HCV-3
Naives  (12 weeks) B/1
Experienced (24 weeks) B/1
HCV-4
Naives (12 weeks) B/2
Experienced (24 weeks) B/2
Abbreviations: SOF, sofosbuvir; PEG-IFN, pegylated interferon; RBV, ribavirin; SMV, simeprevir; BOC, boceprevir; TVR, telaprevir.
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.4.8. SOF plus DCV for 12 (naives) or 24 (experienced) weeks
This  regimen is indicated for HCV-1 infected patients, including
hose who have failed triple therapy with Boceprevir or Telaprevir
lus PEG-IFN and RBV.
The  same regimen is also indicated for HCV-3 (B1) and HCV-4
B2) infected patients.
.5.  From guidelines to clinical practice
The role of SOF in the treatment of chronic hepatitis C is expected
o evolve rapidly, in this phase of great dynamic evolution in the
reatment paradigms of the disease. The indication to when and
ow to use SOF in an optimized way is and will be closely depend-
nt not only on the type of patient to be treated, but even more
n the type of other DAAs available for combination strategies.
OF represents the ﬁrst, and still the most promising, oral agent
gainst HCV and has the historical merit and strength of having
ermitted the switch from IFN-based to IFN-free regimens. Further-
ore, considering the pangenotypic efﬁcacy, and the resistance,
afety and DDI proﬁle, there is almost universal consensus thattion (grading A, B, C)/EASL recommendations: Grading of Evidence (A, B, C) Grading
SOF  is and will remain the ideal backbone drug for most IFN-
free regimens. However, it should also be stated that some of the
SOF-based regimens recommended by the most recent Interna-
tional Guidelines are not optimal and should therefore be used
only in the absence of better options in patients in urgent need of
treatment.
Based on available data from phase II and phase III clinical tri-
als and from emerging evidence in clinical practice, the following
considerations should guide physicians in the use of SOF to treat
hepatitis C:
HCV-1  infected patients: The ideal regimen for these patients
appears to be a combination of SOF with a complemen-
tary DAA. While awaiting the availability of the co-formulated
SOF + Ledipasvir pill, the combination of SOF plus Simeprevir for
12 weeks seems to be the best choice for these patients, indepen-
dently of HCV-1 subtype, previous treatments and stage of ﬁbrosis.
The exceptions are: patients who  have failed triple therapy with
Boceprevir or Telaprevir due to cross-resistance with Simeprevir;
patients with severe liver impairment, due to uncertainty as to
simeprevir pharmacokinetics and safety, and patients that need
S nd Liv
t
o
D
a
f
H
h
s
a
m
W
d
r
m
i
f
d
m
t
r
a
W
b
a
b
t
a
1
p
n
c
o
i
t
r
a
1
P
P
t
c
w
f
c
H
m
a
p
w
d
h
o
a
w
T
a
n
p
[
[
[
[
[
Society of America. Recommendations for testing, managing and treating hep-
atitis C; 2014. Available at: http://www.hcvguidelines.org/full-report-view178 A. Alberti, S. Piovesan / Digestive a
o take drugs with signiﬁcant DDI with Simeprevir. An alternative
ption for some of these patients is the combination of SOF with
aclatasvir, if there are no DDI.
The triple regimen of SOF plus PEG-IFN and RBV for 12 weeks is
n excellent strategy for naïve HCV-1 patients that can take inter-
eron, independently of the HCV-1 subtype and of stage of ﬁbrosis.
owever, this regimen has not been tested in HCV-1 patients who
ave failed PEG-IFN and RBV, and although modelling by FDA has
uggested that SVR could reach 71% in this setting, it seems reason-
ble to believe that this regimen could be adequate for relapsers,
uch less for partial responders and even less for null responders.
hether longer treatment duration could improve SVR in these
ifﬁcult to treat patients is unknown, and therefore difﬁcult to
ecommend.
The dual SOF + RBV oral combination appears suboptimal in
ost, if not all, HCV-1 patient categories in terms of achiev-
ng virus eradication, while it is relatively effective in achieving
ull suppression of HCV replication on therapy, even long term,
ue to the high barrier to resistance. This allows the achieve-
ent of complete HCV-RNA negativity in serum in patients on
he liver transplant waiting list and efﬁciently prevents HCV
ecurrence after transplant in patients who receive the allograft
fter having undetectable serum HCV-RNA for at least 4 weeks.
hether long-term suppression of HCV replication by the com-
ination of SOF plus RBV can also stabilize/improve patients with
dvanced, decompensated cirrhosis remains to be better clariﬁed
y ongoing studies, but this strategy will most likely be substi-
uted in the near future by more effective DAA combinations,
nd this should be expected particularly for patients with HCV-
. It should be mentioned, however, that the combination of SOF
lus RBV for 24 weeks has given excellent SVR rates in HCV-1
aïve patients coinfected with HIV, suggesting that this strategy
ould be a valid option in this setting, where addition of a sec-
nd/third DAA could be problematic due to several drug–drug
nteractions.
HCV-2 infected patients: In these patients there is clear evidence
hat the combination of SOF + RBV is an excellent option, and supe-
ior to all other available options in terms of efﬁcacy, tolerability
nd safety. Guidelines recommend the prolongation of therapy to
6–20 weeks in patients with cirrhosis and/or previous failure with
EG-IFN plus RBV. In these patients a triple regimen with SOF plus
EG-IFN plus RBV for 12 weeks should also be considered, when
he patient is still eligible for PEG-IFN.
HCV-3 infected patients: Based on available data, these patients
an be treated with SOF plus PEG-IFN plus RBV for 12 weeks or
ith SOF + RBV for 24 weeks. The former regimen should be pre-
erred in patients that are still eligible for PEG-IFN, particularly
irrhotics or with previous failure to respond to PEG-IFN plus RBV.
owever, in the most difﬁcult to treat HCV-3 patients, these regi-
ens remain suboptimal and the combination of SOF plus DCV, if
vailable, should also be considered.
HCV-4 infected patients: These patients can be treated with SOF
lus PEG-IFN plus RBV for 12 weeks or with SOF plus RBV for 24
eeks. These regimens are adequate for naïve patients, indepen-
ently of liver disease stage. Little data is available for patients that
ave failed PEG-IFN plus RBV, and in these cases the combination
f SOF with SMV  (or DCV) should be preferred, if these drugs are
vailable.
HCV-5,6 infected patients: There are limited data with SOF, as
ell as with any other HCV DAA, in these rare HCV genotypes.
he regimen of SOF plus PEG-IFN plus RBV for 12 weeks and, in
lternative, SOF plus RBV for 24 weeks seems adequate, at least for
aïve patients, until more data is available from trials and clinical
ractice.
[er Disease 46 (2014) S174–S178
3.  Conclusions and perspectives
Sofosbuvir  is a potent, HCV pangenotypic DAA with a high
barrier to resistance and ideal DDI and safety proﬁle, which has
ushered in a new era in the treatment of hepatitis C, as the ﬁrst
drug that can be used to cure HCV infected patients without IFN.
The simpliﬁed SOF plus RBV combination is highly efﬁcacious in
HCV-2 patients when given for only 12 weeks. This same combi-
nation, given for 24 weeks, has been shown to provide beneﬁts
also in patients infected with other HCV genotypes, such as HCV-3,
HCV-1 and HCV-4. In these patients, however, optimized IFN-free
use of SOF requires its combination with a second complementary
DAA, such as Simeprevir, Daclatasvir or Ledipasvir, depending on
the HCV genotype. In this respect, SOF is and will certainly remain
in the near future the fundamental backbone of the most effec-
tive, safe and easy to use IFN-free regimens to cure the different
categories of HCV-infected individuals.
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